[Effectiveness of eculizumab in the treatment of paroxysmal nocturnal hemoglobinuria]
Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Regueiro A
Record ID 32011000968
Spanish
Authors' objectives:
The purpose of this report is to assess the evidence available on the efficacy, safety and coverage policy-related issues of eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Authors' recommendations:
The available evidence shows that eculizumab is effective in reducing complement-mediated hemolysis. The evidence is not very strong since there is no CRCT conducted on prevention of thrombotic events. It has not been determined if eculizumab therapy increases survival of PNH patients yet.Although some private insurance companies in the United States give coverage to certain patients, most health systems in different countries do not cover it due to its high costs and because it provides marginal benefits when compared with standard care for PNH.
Details
Project Status:
Completed
URL for project:
http://www.iecs.org.ar/iecs-visor-publicacion.php?cod_publicacion=1242&origen_publicacion=publicaciones
Year Published:
2011
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Antibodies, Monoclonal
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.